Generex Biotechnology Corporation is a Canada-based Company, which develops drug delivery systems and technologies for the treatment of diabetes. The Company has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity. Its buccal insulin spray product, Generex Oral-lyn is in Phase III clinical trials at several sites around the world. The Company’s proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company’s proprietary RapidMist device. Generex Biotechnology Corporation (OTCMKTS:GNBT) stock opened at $ 0.04 in last trading session, and closed at $0.0390, trading in the range of $0.04 – $0.04. The stock showed a negative weekly performance of -20.00%.
IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI), announced the receipt of approximately $3.1 million as its first payment relating to commercial sales of dexmethylphenidate hydrochloride extended-release capsules by its licensee Par Pharmaceutical, Inc. (“Par”). This represents the Company’s share of profits for the 15 and 30 mg strengths of the drug product for the period commencing with the first commercial sales of those strengths on November 19, 2013 and ending December 31, 2013 under its License and Commercialization Agreement with Par. IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) shares closed at $4.01 on last trade day, by gaining 8.09%. Stock 52 week range is $1.50 – $6.46. Company’s market capitalization is $85.10 million.
Delcath Systems, Inc. (NASDAQ:DCTH) announced that the Institut für das Entgeltsystem im Krankenhaus (InEk), the German federal reimbursement agency, has reiterated the Value 4 coverage status for the treatment of patients with liver metastases with the Delcath Hepatic CHEMOSAT® Delivery System. Under the Neue Untersuchungs und Behandlungsmethoden (NUB) reimbursement scheme, Value 4 Status, while not mandating reimbursement, allows participating cancer centers to negotiate reimbursement coverage for the CHEMOSAT procedure with all insurers serving their region. Delcath Systems, Inc. (NASDAQ:DCTH) stock advanced 2.57% and finished the last session at $0.319. The EPS of the stock remained -0.40. Company’s market capitalization is $40.29 million.
Valeant Pharmaceuticals Intl Inc (NYSE:VRX)has agreed to pay up to $500 million to acquire PreCision Dermatology Inc ., a specialty-drug company that has grown quickly since its formation just more than three years ago. Valeant will pay $475 million cash and will pay $25 million more if PreCision reaches a sales-based milestone. The sale will produce returns for PreCision investors, which include Boston Millennia Partners , Essex Woodlands, Frazier Healthcare, Longitude Capital, NovaQuest Capital Management and Quaker Partners. PreCision Chairman Bill Crouse declined to discuss the amount of venture capital PreCision raised. Valeant Pharmaceuticals Intl Inc (NYSE:VRX) stock opened at $135.67 in last trading session and closed at $133.36. The 52 week range of the stock is $64.05 – $140.36 and the day range was $132.48 – $137.99.